Mirum Pharmaceuticals (MIRM) Stock Forecast, Price Target & Predictions
MIRM Stock Forecast
Mirum Pharmaceuticals stock forecast is as follows: an average price target of $57.25 (represents a 31.67% upside from MIRM’s last price of $43.48) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
MIRM Price Target
The average price target for Mirum Pharmaceuticals (MIRM) is $57.25 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $75.00 to $39.00. This represents a potential 31.67% upside from MIRM's last price of $43.48.
MIRM Analyst Ratings
According to 8 Wall Street analysts, Mirum Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for MIRM stock is 0 'Strong Buy' (0.00%), 8 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Mirum Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 12, 2024 | Dae Gon Ha | Stifel Nicolaus | $70.00 | $40.55 | 72.63% | 60.99% |
| Aug 08, 2024 | Brian Skorney | Robert W. Baird | $44.00 | $38.96 | 12.94% | 1.20% |
| Jun 17, 2024 | Gavin Clark-Gartner | Evercore ISI | $62.00 | $33.00 | 87.88% | 42.59% |
| Jun 17, 2024 | Michael E Ulz | Morgan Stanley | $57.00 | $33.00 | 72.73% | 31.09% |
| Jun 17, 2024 | Ed Arce | H.C. Wainwright | $66.00 | $30.99 | 112.97% | 51.79% |
| Jun 17, 2024 | Brian Skorney | Robert W. Baird | $39.00 | $29.71 | 31.27% | -10.30% |
| May 23, 2024 | Joshua Schimmer | Cantor Fitzgerald | $45.00 | $25.75 | 74.79% | 3.50% |
| Apr 16, 2024 | Dae Gon Ha | Stifel Nicolaus | $48.00 | $24.01 | 99.92% | 10.40% |
| Mar 14, 2024 | Ed Arce | H.C. Wainwright | $58.00 | $28.17 | 105.89% | 33.39% |
| Jan 10, 2023 | - | Leerink Partners | $39.00 | $20.02 | 94.81% | -10.30% |
The latest Mirum Pharmaceuticals stock forecast, released on Nov 12, 2024 by Dae Gon Ha from Stifel Nicolaus, set a price target of $70.00, which represents a 72.63% increase from the stock price at the time of the forecast ($40.55), and a 60.99% increase from MIRM last price ($43.48).
Mirum Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 9 |
| Avg Price Target | $70.00 | $70.00 | $54.33 |
| Last Closing Price | $43.48 | $43.48 | $43.48 |
| Upside/Downside | 60.99% | 60.99% | 24.95% |
In the current month, the average price target of Mirum Pharmaceuticals stock is $70.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 60.99% increase as opposed to Mirum Pharmaceuticals's last price of $43.48. This month's average price target is down 0.00% compared to last quarter, and up 28.84% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 11, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Oct 11, 2024 | Evercore ISI | Underperform | Underperform | Hold |
| Aug 08, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Jun 18, 2024 | JMP Securities | Outperform | Outperform | Hold |
| Jun 17, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Jun 17, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Jun 17, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 03, 2024 | Citigroup | Buy | Buy | Hold |
| May 23, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| May 09, 2024 | Leerink Partners | Buy | Buy | Hold |
Mirum Pharmaceuticals's last stock rating was published by H.C. Wainwright on Oct 11, 2024. The company gave MIRM a "Buy" rating, the same as its previous rate.
Mirum Pharmaceuticals Financial Forecast
Mirum Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $69.55M | $47.73M | $37.50M | $31.60M | $27.91M | $18.78M | $17.48M | $12.89M | $3.14M | $5.00M | $11.00M | - | - |
| Avg Forecast | $117.75M | $110.65M | $102.34M | $94.66M | $95.40M | $81.99M | $75.03M | $70.13M | $67.87M | $38.60M | $30.44M | $28.69M | $24.65M | $20.81M | $15.42M | $8.46M | $62.67M | $1.00M | $17.40M | $12.50M | $10.00M |
| High Forecast | $124.61M | $117.09M | $108.31M | $102.42M | $97.68M | $82.22M | $75.03M | $70.13M | $70.89M | $38.60M | $32.22M | $30.36M | $26.09M | $20.81M | $15.42M | $8.46M | $62.67M | $1.00M | $17.40M | $12.50M | $10.00M |
| Low Forecast | $112.29M | $105.52M | $97.60M | $88.71M | $90.05M | $81.77M | $75.03M | $70.13M | $62.14M | $38.60M | $29.03M | $27.36M | $23.51M | $20.81M | $15.42M | $8.46M | $62.67M | $1.00M | $17.40M | $12.50M | $10.00M |
| # Analysts | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | 1.02% | 1.24% | 1.23% | 1.10% | 1.13% | 0.90% | 1.13% | 1.52% | 0.05% | 5.00% | 0.63% | - | - |
Mirum Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 3 analysts is $70.13M, with a low forecast of $70.13M, and a high forecast of $70.13M. MIRM's average Quarter revenue forecast represents a 0.82% increase compared to the company's last Quarter revenue of $69.55M (Dec 23).
Mirum Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | $-30.07M | $-25.15M | $-70.00M | $-24.21M | $-32.61M | $-30.52M | $-29.14M | $-32.38M | $61.76M | $-41.25M | $-38.93M | $-46.96M | $-36.70M |
| Avg Forecast | $-17.25M | $-16.21M | $-14.99M | $-13.86M | $-13.97M | $-12.01M | $-10.99M | $-10.27M | $-9.94M | $-5.65M | $-4.46M | $-4.20M | $-3.61M | $-2.20M | $-1.63M | $-36.49M | $-6.61M | $-105.51K | $-1.84M | $-23.37M | $-1.06M |
| High Forecast | $-16.45M | $-15.46M | $-14.29M | $-12.99M | $-13.19M | $-11.98M | $-10.99M | $-10.27M | $-9.10M | $-5.65M | $-4.25M | $-4.01M | $-3.44M | $-2.20M | $-1.63M | $-29.19M | $-6.61M | $-105.51K | $-1.84M | $-18.70M | $-1.06M |
| Low Forecast | $-18.25M | $-17.15M | $-15.86M | $-15.00M | $-14.31M | $-12.04M | $-10.99M | $-10.27M | $-10.38M | $-5.65M | $-4.72M | $-4.45M | $-3.82M | $-2.20M | $-1.63M | $-43.78M | $-6.61M | $-105.51K | $-1.84M | $-28.05M | $-1.06M |
| Surprise % | - | - | - | - | - | - | - | - | 3.03% | 4.45% | 15.70% | 5.76% | 9.03% | 13.90% | 17.92% | 0.89% | -9.34% | 390.98% | 21.21% | 2.01% | 34.78% |
4 analysts predict MIRM's average Quarter EBITDA for Mar 22 to be $-36.49M, with a high of $-29.19M and a low of $-43.78M. This is -159.08% lower than Mirum Pharmaceuticals's previous annual EBITDA (Dec 21) of $61.76M.
Mirum Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - | - | $-33.15M | $-23.59M | $-74.04M | $-30.13M | $-36.43M | $-35.71M | $-26.92M | $-36.61M | $57.55M | $-47.11M | $-43.89M | $-50.53M | $-37.20M |
| Avg Forecast | $-3.50M | $-7.17M | $-10.91M | $-14.10M | $-14.21M | $-21.47M | $-22.57M | $-20.08M | $-11.47M | $-30.02M | $-38.01M | $-42.46M | $-47.97M | $-49.53M | $-53.85M | $-41.25M | $14.33M | $-81.92M | $-30.62M | $-24.97M | $-34.57M |
| High Forecast | $-3.29M | $-6.73M | $-10.25M | $-4.23M | $-11.37M | $-20.18M | $-21.21M | $-18.87M | $-6.95M | $-28.21M | $-35.72M | $-39.90M | $-45.08M | $-49.53M | $-53.85M | $-33.00M | $14.33M | $-81.92M | $-30.62M | $-19.98M | $-34.57M |
| Low Forecast | $-3.77M | $-7.71M | $-11.74M | $-23.96M | $-18.47M | $-23.10M | $-24.28M | $-21.60M | $-17.38M | $-32.29M | $-40.89M | $-45.67M | $-51.60M | $-49.53M | $-53.85M | $-49.50M | $14.33M | $-81.92M | $-30.62M | $-29.97M | $-34.57M |
| Surprise % | - | - | - | - | - | - | - | - | 2.89% | 0.79% | 1.95% | 0.71% | 0.76% | 0.72% | 0.50% | 0.89% | 4.02% | 0.58% | 1.43% | 2.02% | 1.08% |
Mirum Pharmaceuticals's average Quarter net income forecast for Mar 22 is $-41.25M, with a range of $-49.50M to $-33.00M. MIRM's average Quarter net income forecast represents a -171.68% decrease compared to the company's last Quarter net income of $57.55M (Dec 21).
Mirum Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - | - | $46.18M | $36.53M | $32.95M | $30.22M | $26.47M | $22.51M | $20.97M | $19.12M | $19.04M | $17.35M | $13.35M | $9.48M | $7.22M |
| Avg Forecast | $165.63M | $155.64M | $143.96M | $133.14M | $134.19M | $115.33M | $105.53M | $98.64M | $95.46M | $54.29M | $42.82M | $40.35M | $34.68M | $29.27M | $21.69M | $11.90M | $88.15M | $1.41M | $24.47M | $4.68M | $14.07M |
| High Forecast | $175.27M | $164.70M | $152.34M | $144.07M | $137.39M | $115.65M | $105.53M | $98.64M | $99.71M | $54.29M | $45.31M | $42.70M | $36.69M | $29.27M | $21.69M | $11.90M | $88.15M | $1.41M | $24.47M | $5.62M | $14.07M |
| Low Forecast | $157.94M | $148.42M | $137.28M | $124.77M | $126.66M | $115.01M | $105.53M | $98.64M | $87.41M | $54.29M | $40.83M | $38.48M | $33.07M | $29.27M | $21.69M | $11.90M | $88.15M | $1.41M | $24.47M | $3.75M | $14.07M |
| Surprise % | - | - | - | - | - | - | - | - | 0.48% | 0.67% | 0.77% | 0.75% | 0.76% | 0.77% | 0.97% | 1.61% | 0.22% | 12.34% | 0.55% | 2.02% | 0.51% |
Mirum Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $98.64M, based on 3 Wall Street analysts, with a range of $98.64M to $98.64M. The forecast indicates a 113.58% rise compared to MIRM last annual SG&A of $46.18M (Dec 23).
Mirum Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 |
| EPS | - | - | - | - | - | - | - | - | $-0.71 | $-0.00 | $-1.94 | $-0.80 | $-0.99 | $-1.02 | $-0.84 | $-1.17 | $1.88 | $-1.55 | $-1.45 | $-1.68 | $-1.43 |
| Avg Forecast | $-0.07 | $-0.15 | $-0.23 | $-0.29 | $-0.30 | $-0.45 | $-0.47 | $-0.42 | $-0.24 | $-0.63 | $-0.80 | $-0.89 | $-1.00 | $-1.05 | $-1.14 | $-1.34 | $0.30 | $-1.73 | $-0.65 | $-0.71 | $-0.73 |
| High Forecast | $-0.07 | $-0.14 | $-0.21 | $-0.09 | $-0.24 | $-0.42 | $-0.44 | $-0.39 | $-0.15 | $-0.59 | $-0.75 | $-0.83 | $-0.94 | $-1.05 | $-1.14 | $-1.34 | $0.30 | $-1.73 | $-0.65 | $-0.71 | $-0.73 |
| Low Forecast | $-0.08 | $-0.16 | $-0.25 | $-0.50 | $-0.39 | $-0.48 | $-0.51 | $-0.45 | $-0.36 | $-0.68 | $-0.86 | $-0.96 | $-1.08 | $-1.05 | $-1.14 | $-1.34 | $0.30 | $-1.73 | $-0.65 | $-0.71 | $-0.73 |
| Surprise % | - | - | - | - | - | - | - | - | 2.96% | 0.00% | 2.44% | 0.90% | 0.99% | 0.97% | 0.74% | 0.87% | 6.20% | 0.89% | 2.24% | 2.38% | 1.95% |
According to 4 Wall Street analysts, Mirum Pharmaceuticals's projected average Quarter EPS for Mar 22 is $-1.34, with a low estimate of $-1.34 and a high estimate of $-1.34. This represents a -171.28% decrease compared to MIRM previous annual EPS of $1.88 (Dec 21).
Mirum Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.37 | $3.67 | 891.89% | Buy |
| INZY | Inozyme Pharma | $2.69 | $14.67 | 445.35% | Buy |
| LRMR | Larimar Therapeutics | $6.13 | $20.33 | 231.65% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.31 | $7.00 | 203.03% | Buy |
| ARQT | Arcutis Biotherapeutics | $10.24 | $31.00 | 202.73% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.34 | $38.80 | 190.85% | Buy |
| LYRA | Lyra Therapeutics | $0.18 | $0.50 | 177.78% | Hold |
| APLS | Apellis Pharmaceuticals | $27.75 | $74.50 | 168.47% | Buy |
| TERN | Terns Pharmaceuticals | $5.71 | $14.25 | 149.56% | Buy |
| KALV | KalVista Pharmaceuticals | $9.33 | $22.67 | 142.98% | Buy |
| IMCR | Immunocore | $32.12 | $70.75 | 120.27% | Buy |
| MLTX | MoonLake Immunotherapeutics | $51.86 | $79.33 | 52.97% | Buy |
| MIRM | Mirum Pharmaceuticals | $43.48 | $57.25 | 31.67% | Buy |
| AMLX | Amylyx Pharmaceuticals | $5.19 | $6.67 | 28.52% | Buy |
| BPMC | Blueprint Medicines | $96.62 | $109.71 | 13.55% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |